ArticlePloS one2015
Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 90 citations in OpenAlex.
- Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers.Clinical and translational science · 2021Trial
- Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.Breast cancer research and treatment · 2020Trial
- Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers.British journal of clinical pharmacology · 2020Trial
- Effects of Green Tea Extract on Atorvastatin Pharmacokinetics in Healthy Volunteers.European journal of drug metabolism and pharmacokinetics · 2020Trial
- Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers.European journal of clinical pharmacology · 2018Trial
- Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.European journal of clinical pharmacology · 2018Trial
- Population nutrikinetics of green tea extract.PloS one · 2018Trial
- Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants.PharmacogenomicsTrial
- Article
- Link between physical activity, nutrition, and antimicrobial pharmacokinetics and therapeutic efficacy: Implications for resistance management.SAGE open medicine · 2026Review
- Epigallocatechin Gallate as a Molecular Therapeutic in Heart Failure and Cardio-Oncology: Mechanistic Pathways and Translational Perspectives.International journal of molecular sciences · 2025Review
- Polyphenols: A top-down approach to nutrition and depression.World journal of psychiatry · 2025Review
- Food Additives Inhibit Intestinal Drug Transporters but Have Limited Effect on In Vitro Drug Permeability.Molecular pharmaceutics · 2025Article
- Unlocking Polyphenol Efficacy: The Role of Gut Microbiota in Modulating Bioavailability and Health Effects.Nutrients · 2025Review
- Catechins and Human Health: Breakthroughs from Clinical Trials.Molecules (Basel, Switzerland) · 2025Review
- Nutrients and Natural Substances for Hypoglycemic Effects and Management in Diabetic Retinopathy.Nutrients · 2025Review
- Green Tea: Current Knowledge and Issues.Foods (Basel, Switzerland) · 2025Review
- Protective Role of Dietary Polyphenols in the Management and Treatment of Type 2 Diabetes Mellitus.Nutrients · 2025Review
- Reversing Morphine Induced Tolerance: Insights Into Cetirizine and Green Tea Extract Efficacy.Current therapeutic research, clinical and experimental · 2025Article
- In Vivo Regulation of Small Molecule Natural Products, Antioxidants, and Nutrients by OAT1 and OAT3.Nutrients · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Green tea catechins inhibit the function of organic anion transporting polypeptides (OATPs) that mediate the uptake of a diverse group of drugs and endogenous compounds into cells. The present study was aimed at investigating the effect of green tea and its most abundant catechin epigallocatechin gallate (EGCG) on the transport activity of several drug transporters expressed in enterocytes, hepatocytes and renal proximal tubular cells such as OATPs, organic cation transporters (OCTs), multidrug and toxin extrusion proteins (MATEs), and P-glycoprotein (P-gp). Uptake of the typical substrates metformin for OCTs and MATEs and bromosulphophthalein (BSP) and atorvastatin for OATPs was measured in the absence and presence of a commercially available green tea and EGCG. Transcellular transport of digoxin, a typical substrate of P-gp, was measured over 4 hours in the absence and presence of green tea or EGCG in Caco-2 cell monolayers. OCT1-, OCT2-, MATE1- and MATE2-K-mediated metformin uptake was significantly reduced in the presence of green tea and EGCG (P < 0.05). BSP net uptake by OATP1B1 and OATP1B3 was inhibited by green tea [IC50 2.6% (v/v) and 0.39% (v/v), respectively]. Green tea also inhibited OATP1B1- and OATP1B3-mediated atorvastatin net uptake with IC50 values of 1.9% (v/v) and 1.0% (v/v), respectively. Basolateral to apical transport of digoxin was significantly decreased in the presence of green tea and EGCG. These findings indicate that green tea and EGCG inhibit multiple drug transporters in vitro. Further studies are necessary to investigate the effects of green tea on prototoypical substrates of these transporters in humans, in particular on substrates of hepatic uptake transporters (e.g. statins) as well as on P-glycoprotein substrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.